News | February 23, 2026
Bavarian Nordic bags $22.5M Canadian vaccine order
The order will cover the manufacturing of bulk vaccine in 2026
The order will cover the manufacturing of bulk vaccine in 2026
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
